Breaking News Instant updates and real-time market news.

ABT

Abbott

$41.17

0.58 (1.43%)

07:48
10/19/16
10/19
07:48
10/19/16
07:48

Abbott reports Q3 Worldwide Medical Devices sales increased 6.4%

Worldwide Medical Devices sales increased 6.4 percent on a reported basis in the third quarter, including a favorable 0.4 percent effect of foreign exchange, and increased 6.0 percent on an operational basis. Worldwide sales of Vascular products increased 5.2 percent on a reported basis in the third quarter, including a favorable 0.3 percent effect of foreign exchange, and increased 4.9 percent on an operational basis. Sales growth in Vascular products was led by double-digit growth of MitraClip, Abbott's device for the treatment of mitral regurgitation, as Abbott continues to build the market for this first-in-class device. Strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera, Abbott's unique stent for the treatment of blockages in the leg. In the quarter, Abbott received U.S. FDA approval for Absorb, the only fully dissolving heart stent. Worldwide Diabetes Care sales increased 11.5 percent on a reported basis in the third quarter, including an unfavorable 1.0 percent effect of foreign exchange, and increased 12.5 percent on an operational basis. International sales growth was driven by continued consumer uptake of FreeStyle Libre, Abbott's revolutionary continuous glucose monitoring system that eliminates the need for finger-sticks. In September, Abbott received U.S. FDA approval for the FreeStyle Libre Pro system, which is designed to help healthcare professionals make better, customized treatment decisions for their patients - and at a significantly lower cost than other professional continuous glucose monitoring systems. During the quarter, Abbott submitted the consumer version of the FreeStyle Libre system for review by the U.S. FDA. The consumer version of the FreeStyle Libre system is designed to eliminate the need for routine finger-sticks and provides glucose data in a simple format that allows people with diabetes to better self-monitor their glucose levels. Worldwide Medical Optics sales increased 4.4 percent on a reported basis in the third quarter, including a favorable 1.9 percent effect of foreign exchange, and increased 2.5 percent on an operational basis. Operational sales growth was driven by continued market uptake of cataract products in the premium intraocular lens segment. In the quarter, Abbott received U.S. FDA approval and launched its TECNIS Symfony intraocular lenses, the first and only lenses in the U.S. that provide a full range of continuous high-quality vision following cataract surgery.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

15:15
03/01/17
03/01
15:15
03/01/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ILG

ILG

$18.88

-0.21 (-1.10%)

15:11
03/01/17
03/01
15:11
03/01/17
15:11
Options
Notable call spread in ILG after earnings were reported yesterday »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:10
03/01/17
03/01
15:10
03/01/17
15:10
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDCE

PDC Energy

$67.59

-4.1 (-5.72%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Upgrade
PDC Energy rating change  »

PDC Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Apr

  • 20

    Apr

JUNO

Juno Therapeutics

$24.04

0.64 (2.74%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Options
Juno Therapeutics options imply 11.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Apr

SBGI

Sinclair Broadcast

$39.90

-0.05 (-0.13%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Hot Stocks
Sinclair Broadcast acquires Tennis Media Company in up to $14M deal »

Sinclair Broadcast Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.46

2.16 (4.57%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Options
Bullish flow in Textron as shares rally »

Bullish flow in Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

, EQY

Equity One

$31.20

-0.46 (-1.45%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$69.37

-0.98 (-1.39%)

, ENDP

Endo

$13.65

0.36 (2.71%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$69.37

-0.98 (-1.39%)

ENDP

Endo

$13.65

0.36 (2.71%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

ENDP

Endo

$13.65

0.36 (2.71%)

, REG

Regency Centers

$69.37

-0.98 (-1.39%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.65

0.36 (2.71%)

REG

Regency Centers

$69.37

-0.98 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

XOP

SPDR Oil Exploration and Production Fund

$38.88

1.0201 (2.69%)

14:51
03/01/17
03/01
14:51
03/01/17
14:51
Options
Hefty put spread in SPDR Oil Exploration and Production ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$41.44

-0.65 (-1.54%)

14:50
03/01/17
03/01
14:50
03/01/17
14:50
Options
Monster Beverage options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$14.25

-0.4 (-2.73%)

14:45
03/01/17
03/01
14:45
03/01/17
14:45
Downgrade
Impax rating change  »

Impax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

14:45
03/01/17
03/01
14:45
03/01/17
14:45
General news
Market remains at record levels in afternoon trading »

Stocks remain sharply…

GD

General Dynamics

$192.22

2.41 (1.27%)

14:43
03/01/17
03/01
14:43
03/01/17
14:43
Hot Stocks
General Dynamics boosts dividend to 84c per share, adds 10M shares to buyback »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$12.26

-0.125 (-1.01%)

, SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Periodicals
Liberty Media: Pandora is 'great product,' 'way undermonetized,' Bloomberg says »

Sirius XM (SIRI) CEO…

P

Pandora

$12.26

-0.125 (-1.01%)

SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

GNW

Genworth

$4.14

0.0501 (1.22%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Conference/Events
Genworth to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

GD

General Dynamics

$192.08

2.27 (1.20%)

14:40
03/01/17
03/01
14:40
03/01/17
14:40
Hot Stocks
Breaking Hot Stocks news story on General Dynamics »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

, SPX

S&P 500

$2,399.94

36.3 (1.54%)

14:38
03/01/17
03/01
14:38
03/01/17
14:38
Technical Analysis
S&P 500 crosses 2400 for the first time »

The S&P 500 (SPX) has…

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

SPX

S&P 500

$2,399.94

36.3 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAR

KAR Auction

$45.02

0.2 (0.45%)

14:33
03/01/17
03/01
14:33
03/01/17
14:33
Hot Stocks
KAR Auction appoints Howse as Chief Commercial Officer »

KAR Auction Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

APD

Air Products

$142.94

2.47 (1.76%)

, MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

14:30
03/01/17
03/01
14:30
03/01/17
14:30
Hot Stocks
Air Products says wins additional Marathon Petroleum supply contract »

Air Products (APD)…

APD

Air Products

$142.94

2.47 (1.76%)

MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CETX

Cemtrex

$3.54

-0.28 (-7.33%)

14:29
03/01/17
03/01
14:29
03/01/17
14:29
Hot Stocks
Cemtrex announces stock buyback of over 200K shares »

Cemtrex announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCA

MDC Partners

$8.75

-0.1 (-1.13%)

14:27
03/01/17
03/01
14:27
03/01/17
14:27
Hot Stocks
MDC Partners received subpoena from Department of Justice »

MDC Partners disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

BUD

AB InBev

$109.93

0.44 (0.40%)

, KR

Kroger

$32.09

0.285 (0.90%)

14:26
03/01/17
03/01
14:26
03/01/17
14:26
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BUD

AB InBev

$109.93

0.44 (0.40%)

KR

Kroger

$32.09

0.285 (0.90%)

BURL

Burlington Stores

$87.24

-1.77 (-1.99%)

JOY

Joy Global

$28.20

0.005 (0.02%)

ANF

Abercrombie & Fitch

$11.25

-0.51 (-4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 02

    Mar

  • 07

    Mar

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.